Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Adds Arthritis Drugs To Fast Track Appraisal Pathway

This article was originally published in The Pink Sheet Daily

Executive Summary

Clinical and cost effectiveness of Rituxan, Orencia, Humira, and Arava to be evaluated under single technology appraisal process.

You may also be interested in...



NICE Says Sequential Use Of TNF Inhibitors To Treat RA Is Not Cost Effective

The agency, however, recommends use of Abbott's Humira, Wyeth's Enbrel and Johnson & Johnson's Remicade to treat RA.

NICE Says Sequential Use Of TNF Inhibitors To Treat RA Is Not Cost Effective

The agency, however, recommends use of Abbott's Humira, Wyeth's Enbrel and Johnson & Johnson's Remicade to treat RA.

Cancer Drugs Move To NICE's Fast-Track Appraisal Process

Guidances for some products could be issued by the end of the year under a new rapid review system.

Related Content

Topics

UsernamePublicRestriction

Register

PS064829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel